

Effectiveness of Canadian travel restrictions in reducing burden of SARS-CoV-2 variants of concern

Angela McLaughlin^{1,2}, Vincent Montoya¹, Rachel L. Miller¹, Canadian COVID-19 Genomics Network (CanCOGeN) Consortium, Michael Worobey³, Jeffrey B. Joy^{1,2,4*}

¹British Columbia Centre for Excellence in HIV/AIDS; British Columbia, V6Z 1Y6, Canada.

²Bioinformatics, University of British Columbia; British Columbia, V5T 4S6, Canada.

³Department of Ecology and Evolution, University of Arizona; Arizona, 85721, United States.

⁴Department of Medicine, University of British Columbia; British Columbia, V5Z 1M9, Canada.

*Corresponding author. Email: jjoy@bccfe.ca

Abstract

Evaluating travel restriction effectiveness in mitigating infectious disease burden is critical for informing public health policy. Here, we quantify where and when variants of SARS-CoV-2 were introduced into Canada to evaluate the extent to which travel restrictions averted viral introductions and COVID-19 case burden. Our results suggest that, across SARS-CoV-2 variants of concern subject to travel restrictions, at least 281 introductions were prevented, accounting for an averted burden of approximately 44,064 cases. This corresponds to approximately 441 averted hospitalizations, 24 averted deaths, and cost savings to Canadian health care systems of approximately 11.2 million Canadian dollars. Travel restrictions were found to be most effective when implemented rapidly during exponential case growth in the focal source and when global circulation was limited. Our analyses reveal that COVID-19 travel restrictions mitigated case burdens and highlight their value in future pandemic response.

Summary

COVID-19 travel restrictions against variants worked and were most effective when implemented rapidly and preceding new variants' wider circulation.

Introduction

Emergence and successive sweeps of SARS-CoV-2 variants of concern (VOCs) with elevated transmissibility, immune evasion, and/or virulence (*1*) have challenged effectiveness of COVID-19 non-pharmaceutical interventions (NPI) and vaccines. Reconstructing the emergence and spread of VOCs can illuminate NPI effectiveness in mitigating viral burden, informing policy for ongoing and future pandemics. Phylogenetic analyses of SARS-CoV-2 genomes can be applied to infer viruses' geographic and temporal origins (*2–4*), in addition to informing dynamic nomenclature systems (*5–7*), estimating key epidemiological metrics such as the effective reproduction number (*8*), and corroborating or refuting epidemiological linkage through contact tracing (*9, 10*).

Travel restrictions are a class of NPI applied to mitigate pandemic burden; they include restricted entry of foreign nationals, flight bans, border entry requirements such as testing or vaccination,

1 and quarantine requirements. Globally, evidence for their effectiveness has been mixed (11–15).
2 Some evidence suggests countries where VOCs were first detected had diminishing contributions
3 towards international dispersal over time, particularly those with high global connectivity, calling
4 into question targeted travel restriction effectiveness on domestic case burden (16). Canadian
5 COVID-19 travel restrictions were employed for travellers from regions where VOCs were first
6 detected (**Fig. 1B** and **Supplemental Materials**), but their effectiveness in limiting introductions
7 and case burden has not been characterized.

8
9 Previous evidence suggested the March 2020 entry ban for foreign nationals effectively reduced
10 viral importations into Canada, but was insufficient to prevent new SARS-CoV-2 sublineages from
11 seeding the second wave (4). We hypothesized that subsequent Canadian SARS-CoV-2 variant-
12 specific travel restrictions were associated with reduced introduction rates from focal sources.
13 Second, we hypothesized that these reduced importation rates would translate into reductions in
14 Canadian case burden, and reduced economic impacts. To test these hypotheses, we inferred
15 phylogeographic models of SARS-CoV-2 variant dispersal into and within Canada to evaluate the
16 effectiveness of variant-specific travel restrictions in reducing importations and averting cases. We
17 proportionally subsampled publicly available GISAID sequences available up to March 22, 2022,
18 after which testing frequency dropped, to estimate variant-specific cases for each Canadian
19 province or country. We then inferred maximum likelihood phylogenetic trees for each VOC and
20 variant of interest (VOI) and reconstructed ancestral geographies to estimate the timing, origins,
21 destination, and spread of variants into and within Canada. We estimated the effectiveness of flight
22 bans for Alpha, Delta, and Omicron variants, or enhanced screening for Gamma and Beta variants,
23 in averting viral importations and cases, using a counterfactual approach, whereby expected
24 introductions in the absence of restrictions were predicted in relation to VOC cases in focal sources
25 and travel volume. Our findings highlight that monitoring and statistically analyzing the
26 emergence, introduction, and spread of novel sublineages is crucially important to guide public
27 health responses to ongoing and future epidemics.


28 29 **Results**

30 **Epidemiological synopsis of SARS-CoV-2 variants in Canada**

31 This study spans from November 2020 (2nd wave), when the first VOCs were identified in Canada,
32 until March 2022 (5th wave), dominated by early Omicron lineages BA.1 and BA.2 (**Fig. 1**). Daily
33 variant cases were estimated for each Canadian province by multiplying confirmed diagnoses by
34 the frequency of variants in the GISAID database. While the 2nd wave (August 2020 – March 2021,
35 Fig. 1) was primarily comprised of wild type SARS-CoV-2 lineages ('Other'), VOCs and VOIs
36 gained their foothold during this time. By the 3rd wave (March 2021 – July 2021), wild type
37 lineages were outcompeted primarily by Alpha (307,680 cases in Canada; **Table S3**), with notable
38 contributions of Gamma (93,762 cases), Beta (18,326 cases), Eta (19,067 cases), Iota (8,325),
39 Epsilon (5,591 cases), Zeta (2,906), Kappa (2,838), and Mu (405) across Canada, and even low-
40 level detection of Delta lineages (first sampled in Canada on March 6, 2021). The maximum daily
41 cases of the 2nd and 3rd waves were comparable, with the trough between the 3rd and 4th waves in
42 summer 2021 low enough to justify relaxation of interventions. However, the 4th wave spanning
43 August 2021 – December 2021 driven by Delta brought significant burden on the Canadian health
44 care system with 500,617 estimated Delta COVID-19 cases. Early Omicron lineages drove a 5th
45 wave with 630,408 BA.1 cases, 741,437 BA.1.1 cases, and 38,009 BA.2 cases cumulatively in
46 Canada by March 22, 2022.

47

1



2

3 **Fig. 1. Epidemiological dynamics of SARS-CoV-2 variants in Canada.** (A) Estimated daily cases of variants of concern (VOC) and (VOI) in Canada from November 1, 2020 until March 22, 2022. (B) Daily variant introductions into Canada, overlaid with timing of VOC-specific travel restrictions in Canada. Introductions include sublineages, international viral introductions into Canada with sampled descendants, and singletons, international viral introductions without sampled descendants. (C) Cartoon phylogeny of SARS-CoV-2 VOCs and VOIs scaled approximately by divergence from the root.

10


11 **Viral introduction rate reductions from focal sources following travel restrictions**

12 VOC-specific travel restrictions were variably effective in lowering viral introduction rates from focal regions of first detection. The UK flight ban from December 20, 2020 – January 6, 2021 (duration: 17 d; delay from first sample: 44 d) in response to Alpha was associated with a non-significant 1.49 (95% confidence interval, two-sided t-distribution: 0.87-2.12)-fold reduction of the sublineage importation rate within two weeks and a 1.15 (0.91-1.39)-fold reduction of the proportion of sublineages from the UK (Figs. 2A, 3). However, the importation rate held steady amid exponentially rising Alpha cases in the UK (Fig. S23A) and then rebounded following ban repealment, rising to a maximum of 7.6 (6.3-8.8) sublineages from the UK per week on March 3, 2021. There were at least 672 (652-693) Alpha introductions into Canada, including 234 (228-240) sublineages and 438 (418-459) singletons. The UK contributed 50% (46-53%) of sublineages prior to the flight ban, 46% (39-53%) during the ban, and 37% (35-40%) after (Fig. S30). Altogether, 40% (38-42%) of sublineages and 45% (43-48%) of singletons originated in the UK (which represented 20% of international sequences), followed by Europe, the origin of 31% (29-

24

1 32%) of sublineages and 23% (21-25%) of singletons, and the USA, contributing 23% (22-24%)
 2 of sublineages and 26% (25-28%) of singletons.

3



4
 5 **Fig. 2. VOC sublineage introduction dynamics into Canada in the context of COVID-19**
 6 **travel restrictions.** The 7-day rolling average weekly sublineage introduction rates were inferred
 7 using maximum likelihood phylogeography for (A) Alpha, (B) Beta, (C) Gamma, (D) Delta, and
 8 (E) Omicron, BA.1 and (F) BA.1.1. Most introductions of Omicron BA.2 came after travel
 9 restrictions and thus BA.2 was excluded here. Global regions contributing most sublineages were
 10 directly annotated. 95% confidence intervals across 10 bootstraps for focal regions of first VOC
 11 detection are displayed and additionally for the USA for BA.1 and BA.1.1. Travel restriction
 12 durations for each variant shown with shaded grey rectangles.

13

14 For Beta, enhanced screening and quarantine enacted for travellers who had been to South Africa,
 15 effective December 24, 2020 - February 22, 2021 (duration: 60 d; delay from first sample: 5 d),
 16 was associated with a significant 6.25 (2.72-9.78)-fold reduction of the Beta sublineage
 17 importation rate from South Africa, as well as a 1.75 (1.33-2.18)-fold reduction of the proportion
 18 of sublineages from South Africa (Figs. 2B, 3). During the restriction, there was a rise in Beta
 19 sublineages likely to have originated in Europe and other African nations; following restrictions,
 20 Beta importations from Asia increased. Overall, of 40 (40-41) total estimated sublineages, 14%
 21 (12-16%) were likely from South Africa, 31% (30-33%) from Asia, and 20% (18-22%) from other
 22 African nations (Fig. S39). Of 80 (77-83) total singletons, 8% (7-9%) were likely from South
 23 Africa, while 41% (39-42%) were from Asia, 22% (19-24%) from Europe, and 18% (17-20%)
 24 from other African nations.

25


1 Neither of the Gamma-related restriction periods with enhanced screening for travellers from
2 Brazil was associated with significant reduction in sublineage importations from Brazil into
3 Canada (**Figs. 2C, 3**). The second period of restrictions from March 30 to April 14 (duration: 15
4 d) was associated with a significant 1.6 (1.27-1.93)-fold reduction in the proportion of sublineages
5 from Brazil; however, the number of Gamma sublineages observed during this period ($n=3$) was
6 relatively low. Brazil was the likely origin for 52% (50–55%) of the 38 (37-40) Gamma
7 sublineages in Canada, while the USA accounted for 29% (26-32%), other South American nations
8 for 12% (10-14%), and other North American nations for 6% (5-8%) (**Fig. S33**). Of 159 (148-170)
9 total Gamma singletons, 65% (63-67%) were likely from Brazil.

10
11 Suspension of flights from India to counter the Delta variant from April 22, 2021 to September 26,
12 2021 (duration: 157 d; delay from first sample: 47 d) was associated with a significant 2.4 (1.8-
13 3.0)-fold reduction of the sublineage importation rate from India within two weeks and 7.5 (4.6-
14 10.4)-fold within four weeks from a maximum of 19.0 (17.5-20.5) sublineages per week on April
15 24 (**Fig. 2D**). The singleton importation rate from India was also significantly reduced (**Figs. 3,**
16 **S45**). By late June 2021, Delta sublineage importation from the USA and Europe superseded India,
17 and for the USA in particular, continued to rise to a maximum of 20.7 (16.8-24.6) sublineages per
18 week on December 4, 2021. There were at least 1822 (1794-1850) Delta introductions into Canada,
19 including 537 (521-553) sublineages representing 90 (86-93) unique Pango lineages, and 1285
20 (1253-1317) singletons. The flight ban was additionally associated with a 3.8 (3.6-4.1)-fold
21 reduction in the proportion of sublineages originating from India (**Fig. 3**). Prior to the restriction,
22 95% (93-97%) of 76 (72-80) Delta sublineages were from India, compared to 25% (23-26%) of
23 228 (218-237) sublineages introduced during the restriction (**Fig. S43**). After the flight ban, 233
24 (225-240) additional sublineages were introduced, primarily from the USA, Europe, and with a
25 lesser contribution from India. Overall, the USA was the likely origin for 48% (47-49%) of Delta
26 sublineages and 50% (49-52%) of singletons, followed by India for 26% (25-27%) of sublineages
27 and 21% (20-22%) singletons, and then Europe for 19% (18-20%) of sublineages and 20% (19-
28 21%) of singletons (**Fig. S44**). India and the USA accounted for 15% and 42%, respectively, of
29 global sequences sampled. The flight ban was also associated with a reduction of sister lineage
30 Kappa (B.1.617.1) sublineage and singleton importation rates from India (**Fig. S42**).

31
32 The Omicron-related entry ban for foreign nationals arriving from southern African nations and
33 enhanced screening for Canadians who had been to southern Africa (duration: 22 d) was largely
34 ineffective towards reducing importations of BA.1 and BA.1.1. No BA.2 was known to have been
35 introduced prior to the travel restrictions; therefore, we cannot comment upon the effect travel
36 restrictions may have had on BA.2 introductions to Canada. The flight ban was not significantly
37 associated with a reduction in the BA.1 or BA.1.1 sublineage importation rates from southern
38 Africa two weeks following the restriction (1.7 (0.2-3.2)-fold reduction in BA.1 and 0.49 (-0.03 -
39 1)-fold reduction in BA.1.1; **Figs. 2E-F, 3**). There was a significant 2.4 (1.3-3.6)-fold reduction in
40 the proportion of BA.1 sublineages from southern Africa following the ban, which changed from
41 3% (1-5%) of sublineages with southern African origins before restrictions to 1% (1-2%) during
42 restrictions (**Fig. S50**); however, this coincided with increased importation rates from the USA,
43 reaching a maximum of 74.2 (71.0-77.4) BA.1 sublineages per week on December 17, 2021 (**Fig.**
44 **2E**). There was no significant reduction (1.75-fold reduction, 0.4-3.1) in the proportion of BA.1.1
45 sublineages from southern Africa two weeks following restriction implementation. Before, during,
46 and after the restrictions, BA.1.1 sublineages in Canada predominantly originated from the USA,

1 which was the source of up to 128.2 (114.9-141.6) sublineages per week on December 21, 2021
2 (Fig. 2F). By contrast, the maximum flow of BA.1.1 from southern Africa was 0.93 (0.1-1.76)
3 BA.1.1 sublineages per week on November 18, 2021 and 1.8 (0.9-2.7) BA.1 sublineages per week
4 on December 3, 2021. The USA was the predominant source of Omicron BA.1 and BA.1.1 into
5 Canada up to March 2022, contributing 72% (70-73%) of 615 (596-633) BA.1 sublineages (Fig.
6 S50), 90% (89-91%) of 1148 (1103-1194) of BA.1.1 sublineages (Fig. S51), 74% (73-75%) of
7 3634 (3524 - 3744) BA.1 singletons, and 92% (91-93%) of 5572 (5337 - 5806) of BA.1.1
8 singletons. Africa and South Africa combined likely contributed 1% (1-2%) of BA.1 sublineages,
9 <1% BA.1.1 sublineages, 2% (1-2%) of BA.1 singletons, and <1% BA.1.1 singletons.
10 Predominant sources of early BA.2 introductions were India and the UK, and negligibly few BA.2
11 introductions originated from the USA or Africa (Fig. S52). Sequences from the USA represented
12 40% of international sequences subsampled for BA.1 and 66% for BA.1.1; i.e., USA introductions
13 exceeded what would be expected by chance.

14
15 Comparing VOCs according to fold-reduction in sublineage importations (Fig. 2, 3), Delta and
16 Beta restrictions were associated with significant reductions in sublineage importation rate from
17 focal sources 2- and 4-weeks following implementation and the proportion of sublineages from
18 the focal source. However, Beta restrictions were not associated with significant reductions in
19 singleton rates from South Africa, and estimates have wide uncertainty due to rare events. The
20 second Gamma intervention was associated with significant reductions in singleton importation
21 rates from Brazil 2- and 4-weeks after implementation, but not sublineage importation rate. The
22 Delta-related India flight ban was associated with significant reductions in both absolute and
23 relative sublineage and singleton contributions from India to Canada within two and four weeks
24 of implementation. However, these reductions in importations were eventually eclipsed by the
25 influx of sublineages from the USA and other countries not specified in the respective travel
26 restrictions.



28
29 **Fig. 3. Comparison of fold-reduction in VOC importations from focal sources following**
30 **travel restrictions.** Metrics include fold-reduction of the 7-day rolling average sublineage
31 importation rates or singleton importation rates from focal sources two and four weeks after
32 restrictions began; and fold-reduction of the proportion of sublineages or singletons originating
33 from focal sources before versus during travel restrictions. Diamonds show the mean and vertical
34 lines depict 95% confidence interval across ten bootstraps. Estimates were not shown where
35 comparisons included a zero. Dotted line at $y=1$ represents the null expectation of no change.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Introductions and cases averted via VOC travel restrictions

We applied counterfactual models relating introductions to variant cases in focal sources to quantify how many sublineages, singletons, and cases were averted due to travel restrictions. Averted travellers were estimated based on epochal and seasonal trends in international air arrivals (**Supplementary Methods**).

In the absence of the UK flight ban, we estimated there were likely to have been 724 additional travellers from the UK, 12 (9-16) additional Alpha sublineages that could have resulted in upwards of 5,682 (3,849-7,132) descendant cases, as well as 58 (44-73) singletons (**Fig. 3A**). The ban became more effective over time as daily Alpha cases in the UK rose during the latter part of the flight ban (**Fig. S23**). Significantly more sublineages, singletons, and cases were averted per day in the late period (December 28, 2020 – January 6, 2021) versus early period (December 20-27, 2020), with over three times as many sublineages averted per day in the late period (**Fig. 4**). In totality, these 5,740 (3,893-7,205) averted cases represent an additional 1.8% (1.2-2.2%) of all the 324,547 estimated Alpha cases detected in Canada. When normalized to the restriction duration of 17 days, an average of 338 (229-424) cases were averted per day during the UK flight ban; which for the late period was even higher at 482 (380-637) cases averted per day.

Enhanced screening for travellers from South Africa countering the Beta variant averted only 3 travellers, 5 (0-10) Beta sublineages, and 1 (-4-6) singletons (**Fig. 4**). Consistent with Alpha, the early (24 December 2020 – 21 January 2021) and late (22 January – 22 February 2021) periods of the ban displayed contrasting dynamics, although for Beta, effectiveness lessened. The early period was associated with 9 (6-11) averted sublineages that could have resulted in 1,645 (1,551-1,739) descendant cases, while the late period was associated with -4 (-6--2) averted sublineages (more observed than expected in the absence of the ban). Assuming their conservative net sum of 5 (0-10) sublineages averted, there were 1,019 (0-2,111) descendant cases averted. These averted cases would have represented an additional 8.2% (0-16.2%) of the 12,462 total estimated Beta cases in Canada (**Fig. 3B; Fig. S24**). The average effectiveness for Beta was relatively low at 17 (0-34) cases averted per day, but the late period may have averted up to 59 (44-79) cases per day.

Initial enhanced screening for travellers from Brazil countering Gamma averted more travellers, introductions, and cases than the second intervention period (**Fig. 4; Fig. S25**). The first intervention averted 326 travellers, 4 (3-6) sublineages that may have given rise to 7,932 (4,081-9,839) descendant cases, and 4 (-15-22) singletons. Averted sublineages during the first period had a relatively high probability of being large based on the right-skewed distribution of observed Gamma sublineage sizes until the end of restrictions. 7,935 (4,066-9,862) total averted cases during the first intervention represents an additional 7.4% (3.8-9.2%) of the estimated Gamma cases in Canada, and an average effectiveness of 209 (107-260) cases averted per day. The second intervention period was less effective, likely averting 58 travellers, -1 (-2-0) sublineages, and 2 (-3-7) singletons.


The India flight ban was effective in averting many travellers, sublineages, singletons, and cases, however it diminished in effectiveness as Delta cases increased globally (**Fig. 4**). Over five months, the ban likely averted 5,148 travellers from India. The number of daily travellers averted was steadily high from late April to mid-June 2021, dropping in July 2021 before becoming erratic

1 with rising travel volume via other countries, which was permitted with a negative PCR test
2 (**Figures S19**). 63 Delta sublineages were observed during restrictions, whereas we predicted there
3 would have been 259 (237-280) sublineages imported without restrictions, amounting to 196 (174-
4 217) Delta sublineages averted throughout the entire flight ban (**Fig. S26**). There were more
5 sublineages averted in the first period of the ban up to the end of June (2 (2-2) sublineages averted
6 per day) compared to July through September when the ban ended (1 (1-1) sublineages averted per
7 day). Averted sublineages could have given rise to 25,935 (22,431 – 29,891) cases. An additional
8 525 (338-711) singletons were averted or 3 (2-5) singletons averted per day. More singletons were
9 averted in the first period of the ban, 6 (5-7) per day, versus the second period, with 1 (0-2) per
10 day. In totality, 26,460 (23,474-29,819) cases were likely averted. Relative to the 491,733 total
11 estimated Delta cases in Canada, this would have represented 5.4% (4.8-6.1%) additional sampled
12 Delta cases. Overall, 165 (147-186) cases were averted per day during the Delta ban; in the first
13 period, 252 (232-271) cases were averted per day, which decreased to 99 (83-116) in the second
14 period. We were unable to test the effectiveness of the two-month flight ban for Pakistan because
15 the sequence representation was low enough to warrant its grouping with Asia; however, we
16 estimated 116 travellers from Pakistan were averted (**Fig. S22**).

17
18 For Omicron, the entry ban for foreign nationals and enhanced screening for Canadians who had
19 travelled to southern Africa nations was largely ineffective in reducing Omicron burden (**Fig. 4**).
20 Although it may have averted 1,681 travellers from Africa, 4 (2-6) BA.1 and 8 (6-11) BA.1.1
21 sublineages, as well as 1,607 (823-2349) BA.1 cases and 1,838 (1364-2247) BA.1.1 cases, these
22 were negligible compared to the massive burden of Omicron. The cases averted by southern Africa
23 entry restriction represented only 0.3% (0.1-0.4%) of 634,334 BA.1 cases and 0.2% (0.2-0.3%) of
24 779,903 BA.1.1 cases confirmed by March 10, 2022. Overall intervention effectiveness was 73
25 (37-107) BA.1 and 84 (62-102) BA.1.1 cases averted per day. The second period of the
26 intervention was more effective than the first period of the intervention at 161 (82-198) BA.1 cases
27 and 137 (93-184) BA.1.1 averted per day. Omicron cases per day in South Africa and other African
28 nations were higher in the second period of the intervention than the first (**Fig. S27, S28**). We did
29 not find any evidence of BA.2 sublineages introduced from either South Africa or Africa, and only
30 one singleton which likely was introduced in mid-February (**Fig. S53**).

31
32 Overall, variant-specific restrictions were variably effective, but conservatively may have averted
33 at least 281 introductions and 44,064 additional cases in Canada. The majority of cases averted
34 were Delta (25,922), followed by Gamma (7,937 v), Alpha (5,740), Omicron BA.1.1 and BA.1
35 (3,445), and Beta (1,020). The restrictions that averted the highest percentage of cases relative to
36 the variant case burden observed in Canada were Beta (8.2%, with the caveat of wide uncertainty
37 and relatively low burden), the first Gamma intervention (7.4%), Delta (5.3%), Alpha (1.8%), and
38 lastly, Omicron BA.1 (0.3%) and BA.1.1 (0.2%). Comparing restrictions' effectiveness in terms
39 of cases averted per day, Alpha was the most effective (338 per day), followed by the first period
40 of Delta (252 per day), the first Gamma intervention (209 per day), and Omicron BA.1 and BA.1.1
41 (157 per day).

42



1
2 **Fig. 4. Averted introductions and cases attributable to VOC travel restrictions.** Sublineages,
3 singletons, and estimated cases averted overall and normalized to intervention duration;
4 and percent additional cases averted relative to total variant cases in Canada. Metrics were estimated
5 for entire intervention and for early and late periods of the intervention. Gamma interventions were
6 considered only separately.

7
8 Based on cases averted, average COVID-19 hospitalization and death rates, and estimated public
9 healthcare cost of a COVID-19 patient in Canada, we conservatively estimated averted
10 hospitalizations and deaths, and corresponding costs averted. Between May 2020 and April 2021,
11 the average COVID-19 hospitalization rate in the USA was estimated as 1093.9 per 100,000
12 (1.1%) (17). Therefore, without considering differences in variant virulence or age demographics,
13 we coarsely assume 1% of COVID-19 cases averted could have been hospitalized. The average
14 cost per COVID-19 patient hospitalization in Canada was \$15,000 for those not in ICU and

1 \$55,000 for those admitted to ICU, with financial information up to May 2023 (18). Across data
2 up to March 2022, 21% of hospitalized COVID-19 patients were admitted to the ICU (18), of
3 whom 56% received ventilation and 25% died in the facility. Correspondingly, approximately 441
4 COVID-19 hospitalizations were averted, of which 93 may have been admitted to ICU, and 24
5 may have died. The cumulative medical cost of these averted instances is approximately
6 \$11,214,364 Canadian dollars (CAD). We do not consider the additional costs (and suffering)
7 incurred by families and friends, funeral and estate costs, or diminished economic activity due to
8 employee absences.

9 **Discussion**

11 Our findings suggest that Canadian COVID-19 travel restrictions were variably effective towards
12 reducing SARS-CoV-2 VOC importations and cases, but cumulatively may have averted more
13 than 280 introductions, 44,000 cases, 440 hospitalizations, and 24 deaths; conservatively
14 corresponding to an estimated savings greater than \$11.2 million CAD. We developed a novel
15 methodology to estimate introductions and cases averted which applies a counterfactual model
16 considering estimated variant cases in focal origins, travel volume, and their empirical
17 relationships with introductions into Canada. This enabled us to both quantify the overall
18 effectiveness of interventions on case burden, but also quantify effectiveness over time, providing
19 retrospective insights into when restrictions could have ended.

21 The India flight ban against Delta introductions was the most effective restriction, corresponding
22 to a large decline in the importation rate from India and averting over 30,000 additional cases.
23 However, the ban's effectiveness decreased past June 2021, after which Delta cases and
24 importations from the USA and other countries rose and cases in India decreased. Regionally
25 coordinated policy towards the Delta lineage by Canada, USA, and other high volume travel hubs
26 may have led to further durability in travel restriction effectiveness. Other analyses of Delta
27 transmission dynamics in Canada found early introductions of AY.25 and predecessor of AY.27
28 (which may have arisen in Canada) drove Delta burden in Canada, corroborating the futility of
29 later stages of the flight ban (19). Repeated extension of the India flight ban was unnecessary past
30 June 2021, although was likely guided by the precautionary principle due to concerns related to
31 case underreporting and Delta's elevated virulence and transmissibility (20–22). The ban should
32 have been implemented earlier and relaxed earlier in light of evidence that Delta was globally and
33 domestically widespread.

35 Our results suggested the UK flight ban targeting Alpha increased in effectiveness as cases
36 climaxed in the UK, while the Beta enhanced screening for South Africa and Gamma enhanced
37 screening for Brazil became less effective over time and were potentially leakier. Omicron-
38 targeted southern Africa entry bans were largely unsuccessful in reducing importations or case
39 burden, as BA.1 and BA.1.1, followed by BA.2, BA.4, and BA.5, were introduced via other global
40 sources. In instances where the proportion of sublineages from an area was reduced following
41 travel restrictions, but the sublineage importation rate was not significantly reduced, the
42 interpretation is that there the travel restriction had a minor effect. When a new variant has emerged
43 and global regions have similar case trajectories and stable relative travel volumes, then the
44 proportion of introductions should remain constant in the absence of restrictions or if restrictions
45 were entirely ineffective. Where the sublineage importation rate and proportion of sublineages
46 decrease in association with travel restrictions, there is a major effect, particularly if cases were

1 rising in the region targeted by the restriction. The counterfactual approach we have taken allowed
2 us to take into consideration variant cases and travel in the targeted nations to predict sublineage
3 importation rates without restrictions.

4
5 Globally, evidence relating to travel restrictions' effectiveness in reducing COVID-19 burden is
6 mixed. Several reviews on the topic highlight a lack of consensus in methodologies for empirically
7 evaluating COVID-19 interventions' effectiveness, including different definitions or criteria for
8 effectiveness (11, 12, 23). In United Arab Emirates, a decline of transmissions from international
9 sources followed implementation of international travel restrictions in 2020 (14). In Zimbabwe,
10 initial public health interventions delayed onset of community transmission following international
11 introduction during the first waves of COVID-19 (24). The implementation of international travel
12 restrictions and stringent domestic interventions within a zero-COVID policy until the end of 2021
13 in New Zealand eliminated community transmission until the arrival of the Delta variant (21).
14 Other studies found intermediate effectiveness, such as in South Korea, where international
15 traveler quarantine in 2020 reduced introductions and spread of SARS-CoV-2, but control was
16 incomplete (25). Mandatory hotel quarantines in response to the Delta variant reduced onward
17 transmission of Delta importations in England, but subsequent NPI relaxation drove rapid
18 transmission of early introductions (26). As for evidence of low effectiveness, restriction of travel
19 from Brazil to the USA did not prevent establishment of the Gamma variant in New York City, as
20 the majority of Gamma transmission lineages had already been established at least two weeks prior
21 originating from other regions in the USA (13). In Hong Kong, border control measures were
22 deemed insufficient to prevent outbreaks, especially during a period of lower stringency of social
23 restrictions (15). While this by no means comprises a comprehensive review of evidence, these
24 examples highlight the lack of consensus regarding how to measure effectiveness and consider the
25 epidemiological circumstances in which a measure was enacted. What can be distilled from this
26 body of work is that, as implemented, travel restrictions do not stop all introductions, but they can
27 reduce the flow, and their impact depends upon the epidemiological, immunological, and
28 stringency context in which they are invoked, as well as their coordination with neighboring
29 countries.

30
31 Many factors can impact travel restriction effectiveness and should be weighed at the time of
32 implementation. Of first consideration are the magnitude and rate of change in prevalence in the
33 country where a variant is first detected, as well as in other geographies that could act as sources.
34 Additionally, importations and cases were most effectively averted when restrictions were
35 implemented rapidly. Part of the reason the Omicron ban may have been less effective is that it
36 was discovered on November 19, 2021, over a month following its estimated origin around
37 October 9, 2021 (27). By the time restrictions were implemented for travel from southern Africa,
38 Omicron had already dispersed globally, and the USA was a dominant early exporter of BA.1
39 globally (16). The Delta-related flight bans commenced 47 days after the first Delta case was
40 sampled in Canada, and Beta-related measures began 5 days after first detection. The extent of
41 variant spread during this delay is affected by the focal geographies' global travel volume and
42 degree of connectedness (16), as well as a variant's inherent transmissibility. Another factor is a
43 variant's antigenic distance and immune evasion potential, which in combination with
44 immunological waning from natural infections and vaccines, determine the extent of population-
45 level susceptibility and thus potential for introductions to become large outbreaks. Outbreak sizes
46 can also be minimized in the presence of domestic NPIs, such as restrictions on social gathering

1 or mask requirements that reduce contact rates or transmission probabilities, and higher
2 compliance. Legal and logistical travel loopholes could compromise restriction effectiveness by
3 increasing border porosity. For the Delta-related flight bans, there was a loophole whereby
4 travellers from India and Pakistan could enter Canada indirectly through intermediary flights, but
5 were required to present a negative COVID-19 test upon arrival (28). Travel volume from India
6 expanded during later stages of the ban (**Fig. S14**). Variant virulence and rates of hospitalizations
7 and deaths are also important to consider for overall health care burden.

8
9 There are multiple sources of uncertainty and limitations in this analysis. Publicly available
10 genome sequences and confirmed diagnoses over time are affected by differences in case
11 ascertainment across geographies, time, variants, case severity, and sociodemographic groups.
12 Therefore, daily new diagnoses based on PCR confirmed positive cases do not equate to daily new
13 infections. Within any given jurisdiction, there were changes in frequency of symptomatic
14 infection and hospitalization, testing criteria and public health recommendations, testing capacity,
15 and availability of rapid antigen tests (for which results were not always reported). One way to
16 consider changes in age-based testing criteria is to associate fluctuations in case counts among the
17 widely tested 70+ age group, for which testing recommendations did not change in late 2021, with
18 cases in other age groups (29). However, this approach fails to consider differential changes in
19 behaviour and social contact across age groups in response to the pandemic, as well as does not
20 consider other sources of ascertainment bias affecting all age groups. In addition to case
21 ascertainment bias, jurisdictions varied in extent and reason for sequencing, as well as in their
22 proclivity to share this data publicly. When analyzing empirical sequence data sets, where reason
23 for sequencing could be due to hospitalization, association with an outbreak, travel history, or
24 variant suspicion (spike gene target failure requiring variant confirmation, for example), we must
25 interpret frequencies cautiously. An idealized surveillance strategy would be to longitudinally
26 surveil a randomly selected cohort for infection (regardless of symptoms) with all cases sequenced,
27 which would yield accurate estimates of the percent positivity (prevalence), variant frequencies,
28 and levels of re-infection in the wider community. Accurate case counts are important to quantify
29 burden, as well as to inform sequence subsampling strategies to minimize bias.

30
31 Accuracy of phylogeographic inferences has been shown to be high when the migration rate is
32 low, however sampling differences across jurisdictions can contribute to biases (30). We
33 developed a sequence subsampling strategy to reduce sampling bias in the publicly available
34 sequence data, while also rendering the analysis computationally feasible for maximum likelihood
35 phylogenetic inference. With moderately large subsamples of 50,000 sequences, regions that
36 contributed high sequences per case were less overrepresented, but regions with few sequences
37 available relative to cases remain underrepresented. With smaller subsamples, the ratio of
38 sequences to cases can be more normalized but this reduces the data informing the model, and thus
39 it is a fine balance of maximizing signal while ensuring representativeness. Differences in reason
40 for sequencing are also not alleviated via subsampling. Future developments in subsampling and
41 phylogeographic methodologies could profit from structured consideration of reason for
42 sequencing, as well as carrying forward sampling proportion or case ascertainment in the
43 phylogeographic inference. Recent methodological developments to include unsampled nodes in
44 phylogeographic inference are promising, but are at present, not scalable to tens of thousands of
45 sequences (31).

1 Inclusion of 50% Canadian and 50% global sequences in each subsample was based upon findings
2 from previous sensitivity analyses, whereby this relative representation identified the maximum
3 number of sublineages and singletons (4). Additionally, the 50% split imposes a prior expectation
4 that any given sequence from Canada is equally likely to have a close relative from either Canada
5 or global. One might ask, if we are interested in quantifying primarily introduction dynamics from
6 focal sources, why not include more sequences from the focal source relative to other global
7 regions? Doing so would increase the chance of misattributing the origin of a sublineage to the
8 focal source when it could have come from a different country. While the focus is on the dynamics
9 of the focal source sublineage importation rate, contributions from other regions remain important.
10 By treating the focal source equally to other global regions at the subsampling stage, we do not
11 impose a bias towards the focal source in the ancestral reconstruction; thus, our estimates represent
12 lower bounds of sublineages per week, but proportionally and temporally, should be accurate. By
13 subsampling multiple bootstraps with replacement, we considered how the relative inclusion of
14 sequences and geographies affect uncertainty in our estimates of importations and sublineage sizes.

15
16 In addition to uncertainty as to whether sequence sets were representative of the pandemic in
17 Canada and globally, there was also uncertainty due to phylogenetic tree inference, time-scaling
18 the tree under a relaxed molecular clock model, and ancestral character estimation of geographic
19 origins. For 50,000 tips, it is impossible to search the entire tree space for the most likely tree,
20 therefore the trees analyzed represent local maxima. Furthermore, this pipeline requires scaling
21 trees from units of divergence to time, which presupposes a molecular clock rate can be generalized
22 for the tree. Even though a relaxed molecular clock rate was assumed with no fixed mean, a prior
23 variance of 0.2 across the tree was assumed, which could misrepresent the underlying evolutionary
24 process. By partitioning tree inference by variant with a small subset of parental lineage sequences,
25 we have partially accounted for differences in molecular clock rates across variants, including
26 during their emergence. Tip dates inform rescaling the tree, but themselves can be speckled with
27 errors, for instance due to delay between infection and sampling, data entry errors, and in some
28 cases, incomplete metadata collection dates. Incomplete dates in the Canadian metadata were dealt
29 with by randomly sampling from potential days. This added some uncertainty to the analysis,
30 particularly in regards to the timing of sublineage introduction dates. Incomplete dates in metadata
31 associated with Canadian samples from particular regions were an ongoing issue despite calls for
32 public access to full data to enable genomic epidemiological surveillance (32–34). In previous
33 analyses for the first two waves of SARS-CoV-2, incomplete tip dates were inferred using least
34 squares dating (35), which slowed the time-scaling of trees and in some cases was intractable due
35 to insufficient memory.

36
37 A comprehensive understanding of how variant dynamics were impacted by travel restrictions
38 requires consideration of changes in the environment, host, and virus. Human behavioral changes
39 relating to contact networks and transmission probability via other non-pharmaceutical
40 interventions should be considered in relation to any detected changes in transmission. Further,
41 heterogeneity in population-level immunity due to vaccination and infection confound our ability
42 to identify changes in sublineage characteristics, such as transmissibility or lifespan. Disentangling
43 the effects of public health interventions from viral genetic adaptations in regards to migration,
44 transmission, and health care burden is a formidable challenge. VOCs vary in their selective
45 advantages to outcompete previously circulating diversity (36), which we have not explicitly
46 considered in these models. This was indirectly considered by stratifying variants in the analysis.

1 Methodological developments on estimating variant-specific reproduction numbers and fitness
2 advantages offer some promise in this regard (37). Of course, as with all models, we have
3 endeavoured to infer sufficiently complex models with as few assumptions as possible while
4 maintaining generalizability. Further developments in bridging phylogeographic inference with
5 mathematical modelling could be fruitful in this regard (38).

6
7 We applied travel volume data in our phylogeographic methods by using it to adjust our null
8 expectation of travel volume from a given country if there had not been a travel restriction imposed
9 on that country. By considering seasonal and epochal changes in travel volume into Canada, we
10 estimated travel volume in the absence of restrictions and travellers averted. This approach
11 considers broad changes in propensity or ability to travel, considering discovery of new variants
12 or changes in vaccination and testing requirements. Although we attempted to adjust models
13 relating sublineage flows to variant cases by travel volume, in practice, these models only
14 improved the goodness-of-fit for the BA.1 model. Further explorations of travellers compared to
15 importations averted are warranted. Another way to use flight data is to model exportation
16 intensities from different regions as the product of the estimated number of infected people in a
17 given geography at a given time by travel volume into a country of interest. This has been applied
18 in place of inferring transmission lineages' origin locations when introductions were identified
19 using binary state ancestral reconstruction (3). Another way to use flight data is to investigate
20 whether phylogeographically inferred importation rates are consistent with expected importation
21 intensities. When available, individuals' travel history can also be used as priors in in travel-aware
22 phylogeographic models (31).

23
24 The questions facing the global community to respond to and learn from SARS-CoV-2 have
25 evolved, as have the methodologies used to approach these questions (39). Combining
26 phylogenetics, mathematical modelling, and machine learning could improve the accuracy of
27 infectious disease forecasting (38). For instance, phylogenetics offer insight into taxonomic
28 groupings for model structuring, estimates of migration rates, and evolutionary rates, which can
29 be incorporated into compartmental models. Models would also benefit from improved variant-
30 specific estimates of selection in the context of vaccine- and natural infection-induced immunity.
31 Longitudinal prospective cohort studies of generalizable populations (i.e., not just those above the
32 age of 70) would be helpful in estimating frequencies of circulating variants or sublineages,
33 positivity rates, period of infectiousness, incidence, and the true sampling rate. Accurate
34 estimations of case ascertainment and relatedly, sampling rates, in the broader population might
35 be estimated compositely from knowledge for specific variants of the difference between expected
36 percent positivity from the cohort vs observed in broader data, as well as knowledge of reason for
37 sequencing in the publicly available data.

38
39 However, we have provided evidence that they reduce the flow of pathogens across borders,
40 particularly when implemented rapidly following initial detection. In instances where viral
41 establishment is nearly inevitable, travel restrictions can contribute to flattening the curve to
42 mitigate the burden on the health care system with limited finite resources. If a government adopts
43 a travel restriction policy to limit burden, we recommend simultaneously adopting other NPI
44 domestically, like installing adequate ventilation and promoting mask use, to prevent introductions
45 from becoming widespread sublineages.

1 Travel restrictions to curb importations from countries where variants are first detected should be
2 considered alongside other public health interventions when sufficient evidence suggests there is
3 a high risk to individual- and population-level human health; equally, they should be repealed if
4 there is strong evidence that the variant is already established or poses a low risk to health.
5 Formalizing coordination among neighboring jurisdictions would increase the odds of successful
6 restrictions. Sustained investment in developing genomic surveillance systems, including in
7 wastewater, cohort surveys, and in wildlife, will enable rapid detection and monitoring of
8 circulating variants. Ongoing deposition of anonymized pathogen sequence data into the public
9 repository, with time and date of sampling, is important to facilitate genomic epidemiology studies.

11 **Conclusion**

12 We have presented robust and novel methods for quantifying effectiveness of public health
13 interventions in reducing pathogen introductions and averting cases, which can contribute to the
14 evidence base considered for future implementation and policy. Ongoing funding and
15 prioritization of viral genomic surveillance programs in humans and the animals will help to
16 mitigate future pandemic threats and curtail the ongoing burden of the COVID-19 pandemic.
17 Without global surveillance, we do not know how widely a variant has spread or how quickly it is
18 spreading, limiting our ability to confidently react to the emergence of new variants or pathogens.

19
20 We conclude by emphasizing that it is critical to consider that travel restrictions can and have had
21 very negative socioeconomic impacts. As such, they provide a strong disincentive to countries that
22 are first to detect new SARS-CoV-2 variants of concern to make those discoveries public. This
23 issue is one that we expect to continue as new subvariants and perhaps entirely new variants of
24 SARS-CoV-2 emerge through time. Even more concerningly, these disincentives can be predicted
25 to contribute to hesitation (or complete reluctance) to report future emerging pathogens on the part
26 of countries first to detect them, likely the countries where they originated. This may contribute to
27 the loss of a window of opportunity to prevent a potential new pandemic from being actualized.
28 The scientific evidence presented here that travel restrictions can have public health benefits needs
29 to be viewed in that larger context.

31 **Methods**

32 **Sequence data sets and curation**

33 9,487,106 SARS-CoV-2 sequences and associated metadata (298,892 collected in Canada) were
34 downloaded from Global Initiative on Sharing All Influenza Data (GISAID) on March 22, 2022
35 (40, 41). GISAID clade partitions were maintained throughout data cleaning to reduce
36 computational burden. Sequences were excluded if they were listed on the Nextstrain exclude list
37 updated on day of data download (n=8,782) (7, 42), duplicate IDs (n=4,284), from a non-human
38 host (n=6,803), environmental samples (n=4,907), or had incomplete dates outside of samples
39 from Canada (n=218,233). For Canadian sequences with incomplete dates, days were randomly
40 sampled within known months. If only year was provided, the sequence was discarded.

41
42 Sequences were aligned to Wuhan-Hu-1 (GenBank ID: MN908947.3) using the viralMSA python
43 wrapper of minimap2 (43, 44). Sequences were excluded if ambiguous sites or gaps exceeded 10%
44 (n=7,968 and n=657,063, respectively), resulting in 8,585,792 total clean sequences (274,568 from
45 Canada). Pango lineages in the metadata were called using pangolin v3.1.20 and pangoLEARN
46 data release March 22, 2022 (5, 6).

1
2 Total clean sequences available were grouped by variant (**Table S3**): Alpha (B.1.1.7, Q.*), Beta
3 (B.1.351), Gamma (P.1), Delta (B.1.617.2, AY.*), Epsilon (B.1.429 and B.1.427), Zeta (P.2), Eta
4 (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Mu (B.1.621), and Omicron (separately: BA.1,
5 BA.1.1, and BA.2). Any sequence not identified as a variant was grouped into ‘Other’. Variants
6 with fewer than 100 sequences from Canada were excluded (Lambda, Theta, GH/490R, and BA.3).
7 The primary manuscript focuses on the five VOCs, Alpha, Beta, Gamma, Delta, and Omicron
8 BA.1, BA.1.1, and BA.2, for which there were targeted travel restrictions. Omicron was split into
9 its comprising Pango lineages as their spatiotemporal origins into Canada differed. The earliest
10 global sample collection dates for each variant were obtained from cov-lineages.org (45) and
11 outbreak.info (46) and earliest Canadian dates were pulled from clean GISAID data (**Table S1**).
12 Canadian sequences with collection dates preceding the earliest global date for each variant were
13 removed.

14

15 **Estimating variant-specific cases by Canadian province and global region**

16 Canadian daily new COVID-19 diagnoses by province were obtained from the Public Health
17 Agency of Canada (47). Global daily new diagnoses by country were obtained from the R package
18 coronavirus (48), which pulls data from the Johns Hopkins University Center for Systems Science
19 and Engineering Coronavirus repository. Rolling 7-day averages of daily new diagnoses were
20 calculated to smooth the data. For global regions, countries were grouped into continents unless
21 their sequence contributions were within the top 95th percentile, which included Brazil, Denmark,
22 France, Germany, India, Japan, South Africa, Spain, Sweden, Switzerland, UK, and USA.

23

24 Average daily variant-specific cases in Canadian provinces and global regions were calculated as
25 the product of average daily new diagnoses and average daily variant frequency based on clean
26 GISAID sequences (**Figs. S4, S6**). Total monthly contributions to variant-specific cases were
27 calculated for each province and global regions, then tallies were grouped by variant to calculate
28 geographies’ proportional contributions to cases of each variant for each calendar month (**Fig. S5,**
29 **S7**). Monthly proportional contributions of each geography to variant-specific cases were used to
30 inform the probability of subsampling a sequence from a given geography and month.

31

32 **Subsampling data to reduce spatiotemporal bias**

33 For each of ten bootstraps, 50,000 sequences were subsampled where possible, including 50%
34 sampled in Canada and 50% sampled globally, which was identified as an optimal split of
35 sequences in previous subsampling sensitivity analyses (4). The temporal distribution of sampled
36 sequences reflected the distribution of monthly estimated variant-specific cases for Canada and
37 global regions, respectively (**Fig. S8**). If there were fewer sequences available than the target of
38 25,000 for a given variant in Canada or global, then all sequences were retained. The proportion
39 of variant cases occurring in each month was multiplied by the total number of target sequences
40 to obtain monthly targets. If fewer sequences were available in any given month than the target,
41 then all sequences from that month were taken. If the target sequences for a given month were
42 available, but sparse (fewer than 500) during the first half of the months where sequences are
43 available, then the number of target sequences was specified as 500 (**Fig. S8**). Remaining
44 sequences were redistributed among months where there were not sparse sequences, and the loop
45 repeated until there were no sparse months and the target number of sequences sampled was

1 achieved. Relative frequencies of variant cases, sequences available (**Table S3**), and sequences
2 sampled (**Figs. S10, S11**) were summarized.

3
4 A small number of sequences were additionally included in each sample set from all parental
5 lineages basal to variants, i.e. for B.1.1.7, sequences were included from lineages B, B.1, and
6 B.1.1. For B, Wuhan-hu-1 was sampled; and for other parental lineages, ten sequences with a
7 collection date preceding that of first global sample for the variant were sampled at random from
8 the global dataset for each bootstrap independently. This was done to provide phylogenetic
9 structure for early branching events and inform the estimation of the timing of variant emergence.

10
11 Sequences were subsampled according to the temporal distributions described above, with
12 probabilities equal to monthly contribution of global regions or Canadian provinces to variant-
13 specific cases, up to the total number of target sequences per month. Subsampling was repeated
14 for ten bootstraps with replacement. Similar subsampling approaches based on countries' cases or
15 deaths have been applied elsewhere (16, 49).

16
17 All 1,752,808 unique subsampled genome sequences from 200 countries and territories were
18 collated into GISAID EPI_SET_230510yr, accessible at doi:10.55876/gis8.230510yr and via the
19 attached Supplemental Table provided by GISAID. This serves as the data acknowledgement for
20 all contributing and submitting laboratories. Those without GISAID Access Credentials may
21 retrieve information about all data contributors by either clicking on the DOI or pasting the
22 EPI_SET ID in the "Data Acknowledgement Locator" on the GISAID homepage.

23
24 **Maximum likelihood phylogenetic inference and ancestral state reconstruction**
25 Problematic sites were censored from sequence alignments prior to phylogenetic inference
26 according to de Maio et al. VCFv4.3 (50). Approximate maximum likelihood trees were generated
27 using FastTree v2.1.11 under a generalized time reversible substitution model and the '-fastest'
28 algorithm (51). Trees were outgroup rooted on Wuhan-hu-1 in R package ape (52). A linear
29 regression of root-to-tip distance versus time was generated for each tree, excluding parental
30 lineage sequences. Tips with absolute value residuals greater than 0.001 or terminal branch lengths
31 longer than 20 mutations were excluded as temporal outliers. Trees were time-scaled using IQ-
32 TREE 2.1.2 with least squares dating (LSD2) (35, 53), a relaxed molecular clock, 0.2 relative
33 variance, and 50 bootstrap resamples to estimate internal branch lengths. Polytomies were
34 randomly resolved.

35
36 Phylogeographic reconstruction of internal nodes' geographic state as Canadian province or global
37 region was conducted using maximum likelihood discrete ancestral character estimation in R
38 package ape with symmetrical rates (52). The highest likelihood state was pulled for each internal
39 node. Canadian sublineages were designated where Canadian internal nodes were preceded by a
40 non-Canadian internal node, signifying an international introduction resulting in onward sampled
41 transmission. Singletons were defined as Canadian sequences with non-Canadian parental origin
42 and no sampled descendants. Sublineage and singleton importation rates were summarized as 7-
43 day rolling mean of importations per week by global region, province of introduction, and Pango
44 lineage. The sum of sublineages and singletons represents a lower limit for the total number of
45 introductions due to subsampling. Rate estimates were reported as the mean across bootstraps,
46 with 95% confidence intervals calculated using the t-distribution, $\mu \pm t \times \sigma/\sqrt{n}$.

1
2 Summary metrics included the fold-reduction of sublineage and singleton importation rates from
3 focal sources two weeks after implementation of restrictions versus before, and fold reduction in
4 proportion of sublineages from focal sources compared to other regions before versus during
5 restrictions. For either metric, the null hypothesis was that restrictions had no effect on either
6 importation rates or proportion of importations from the focal source; therefore, if the 95%
7 confidence intervals do not overlap one, we reject the null hypothesis and have evidence to support
8 restrictions' effectiveness.

9 10 **Estimating cases averted by restrictions**

11 We estimated cases averted due to travel restrictions for each VOC by comparing observed
12 introduction rates to expectations in the absence of travel restrictions, as predicted from a
13 mechanistic counterfactual model of the relationship between introduction rates and variant cases
14 in the focal source, trained on data preceding the intervention. Linear models consistently had the
15 best goodness-of-fit in comparison with Poisson and negative binomial models. Training data were
16 restricted to the week preceding the restriction or where variant cases in the source region exceeded
17 a threshold chosen to maximize the correlation between cases and importations (described for each
18 VOC in supplementary; **Figs. S23-28**). Observed daily variant cases in the focal source during the
19 intervention and expected travel volume were used to predict sublineages per week in the absence
20 of restrictions. Likelihood ratio tests were applied to evaluate inclusion of travel volume as a
21 covariate; it was included for BA.1.1.

22
23 Statistics Canada data on international arrivals (54) was used to quantify observed and estimate
24 expected travel volume from the focal sources in the absence of restrictions based on seasonal and
25 epochal travel changes (**Supplementary Material**). Areas under curves of observed and predicted
26 sublineages per week (converted to per day) were calculated to obtain numbers of sublineages
27 observed and predicted during restrictions, the difference of which equates to sublineages averted.
28 Sublineages averted was calculated for entire intervention durations and for early and late periods
29 (**Fig. 4**). For each averted sublineage, sublineage size (number of sampled descendants) was drawn
30 from VOC-specific gamma distributions fitted to sublineage sizes observed until the end of
31 restrictions. Cases averted from averted sublineages were summed. This was repeated 1000 times
32 to estimate a mean number of total descendant cases averted for the mean and confidence limits of
33 sublineages averted. Confidence intervals were estimated by carrying forward upper and lower
34 limits of importation rates estimated across bootstraps.

35
36 The model fitting process was repeated for singletons by fitting models of singletons per week to
37 variant cases, predicting singletons per week in the absence of restrictions, and taking the
38 difference in observed and expected singletons to estimate the number of singletons averted. Total
39 cases averted is the sum of singletons averted and descendant cases from sublineages averted for
40 each period. The percentage additional cases equals the ratio of total cases averted to total variant
41 cases in Canada overall. Sublineages, singletons, and cases averted were normalized to days of
42 restriction duration. Based on the cases averted and variant-specific hospitalization and death rates
43 in Canada for each variant, we roughly estimated averted hospitalizations, healthcare costs, and
44 deaths.

45 46 **Economic estimations**

1 To approximate health care cost savings attributable to travel restrictions, we translated cases
2 averted to COVID-19 hospitalizations, intensive care unit (ICU) visits, and deaths. Based on a
3 literature search for case hospitalization rates, we assumed an average 1% hospitalization rate
4 throughout the study period, as estimated for the USA between May 2020 and April 2021 of 1093.9
5 hospitalizations per 100,000 cases (1.1%) (17). The average costs of \$15,000 for a COVID-19
6 hospitalization in Canada not in ICU and \$55,000 for those admitted to ICU were obtained from
7 the Canadian Institutes for Health Information (CIHI) (18). We also assume CIHI estimates that
8 21% of COVID-19 hospitalizations resulted in ICU admission, and that 56% of ICU patients
9 received ventilation and 25% died in the facility (18).

10

11 **References**

12

13 1. F. Konings, M. D. Perkins, J. H. Kuhn, M. J. Pallen, E. J. Alm, B. N. Archer, A. Barakat, T.
14 Bedford, J. N. Bhiman, L. Caly, L. L. Carter, A. Cullinane, T. de Oliveira, J. Druce, I. E. Masry,
15 R. Evans, G. F. Gao, A. E. Gorbalenya, E. Hamblion, B. L. Herring, E. Hodcroft, E. C. Holmes,
16 M. Kakkar, S. Khare, M. P. G. Koopmans, B. Korber, J. Leite, D. MacCannell, M. Marklewitz,
17 S. Maurer-Stroh, J. A. M. Rico, V. J. Munster, R. Neher, B. O. Munnink, B. I. Pavlin, M. Peiris,
18 L. Poon, O. Pybus, A. Rambaut, P. Resende, L. Subissi, V. Thiel, S. Tong, S. van der Werf, A.
19 von Gottberg, J. Ziebuhr, M. D. V. Kerkhove, SARS-CoV-2 Variants of Interest and Concern
20 naming scheme conducive for global discourse. *Nat. Microbiol.* **6**, 821–823 (2021). doi: s41564-
21 021-00932-w.

22 2. M. Worobey, J. Pekar, B. B. Larsen, M. I. Nelson, V. Hill, J. B. Joy, A. Rambaut, M. A.
23 Suchard, J. O. Wertheim, P. Lemey, The emergence of SARS-CoV-2 in Europe and North
24 America. *Science*. **370**, 564–570 (2020). doi: 10.1126/science.abc8169.

25 3. L. du Plessis, J. T. McCrone, A. E. Zarebski, V. Hill, C. Ruis, B. Gutierrez, J. Raghwani, J.
26 Ashworth, R. Colquhoun, T. R. Connor, N. R. Faria, B. Jackson, N. J. Loman, Á. O’Toole, S. M.
27 Nicholls, K. V. Parag, E. Scher, T. I. Vasylyeva, E. M. Volz, A. Watts, I. I. Bogoch, K. Khan,
28 C.-19 G. U. (COG-U. Consortium†, D. M. Aanensen, M. U. G. Kraemer, A. Rambaut, O. G.
29 Pybus, Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. *Science*.
30 **371**, 708–712 (2021). doi: 10.1126/science.abf2946.

31 4. A. McLaughlin, V. Montoya, R. L. Miller, G. J. Mordecai, C. C.-19 G. N. (CanCOGen)
32 Consortium, M. Worobey, A. F. Poon, J. B. Joy, Genomic epidemiology of the first two waves
33 of SARS-CoV-2 in Canada. *Elife*. **11**, e73896 (2022). doi: 10.7554/eLife.73896.

34 5. A. Rambaut, E. C. Holmes, Á. O’Toole, V. Hill, J. T. McCrone, C. Ruis, L. du Plessis, O. G.
35 Pybus, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
36 epidemiology. *Nat. Microbiol.* **5**, 1–7 (2020). doi: 10.1038/s41564-020-0770-5.

37 6. Á. O’Toole, V. Hill, O. G. Pybus, A. Watts, I. I. Bogoch, K. Khan, J. P. Messina, T. COVID-
38 19 Genomics UK (COG-UK) consortium, Network for Genomic Surveillance in South Africa
39 (NGS-SA), Brazil-UK CADDE Genomic Network, H. Tegally, R. R. Lessells, J. Giandhari, S.
40 Pillay, K. A. Tumedi, G. Nyepetsi, M. Kebabonye, M. Matsheka, M. Mine, S. Tokajian, H.

- 1 Hassan, T. Salloum, G. Merhi, J. Koweyes, J. L. Geoghegan, J. de Ligt, X. Ren, M. Storey, N. E.
2 Freed, C. Pattabiraman, P. Prasad, A. S. Desai, R. Vasanthapuram, T. F. Schulz, L. Steinbrück,
3 T. Stadler, S. V. S. Consortium, A. Parisi, A. Bianco, D. G. de Viedma, S. Buenestado-Serrano,
4 V. Borges, J. Isidro, S. Duarte, J. P. Gomes, N. S. Zuckerman, M. Mandelboim, O. Mor, T.
5 Seemann, A. Arnott, J. Draper, M. Gall, W. Rawlinson, I. Deveson, S. Schlebusch, J. McMahon,
6 L. Leong, C. K. Lim, M. Chironna, D. Loconsole, A. Bal, L. Josset, E. Holmes, K. S. George, E.
7 Lasek-Nesselquist, R. S. Sikkema, B. O. Munnink, M. Koopmans, M. Brytting, V. S. rani, S.
8 Pavani, T. Smura, A. Heim, S. Kurkela, M. Umair, M. Salman, B. Bartolini, M. Rueca, C.
9 Drosten, T. Wolff, O. Silander, D. Eggink, C. Reusken, H. Vennema, A. Park, C. Carrington, N.
10 Sahadeo, M. Carr, G. Gonzalez, Search Alliance San Diego, National Virus Reference
11 Laboratory, SeqCOVID-Spain, Danish Covid-19 Genome Consortium (DCGC), Communicable
12 Diseases Genomic Network (CDGN), Dutch National SARS-CoV-2 surveillance program,
13 Division of Emerging Infectious Disease (KDCA), T. de Oliveira, N. Faria, A. Rambaut, M. U.
14 G. Kraemer, Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and
15 B.1.351/501Y-V2 with grinch. *Wellcome Open Res.* **6**, 121 (2021). doi:
16 10.12688/wellcomeopenres.16661.2.
- 17 7. J. Hadfield, C. Megill, S. M. Bell, J. Huddleston, B. Potter, C. Callender, P. Sagulenko, T.
18 Bedford, R. A. Neher, Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics.* **23**,
19 62–3 (2018). doi: 10.1093/bioinformatics/bty407.
- 20 8. S. A. Nadeau, T. G. Vaughan, C. Beckmann, I. Topolsky, C. Chen, E. Hodcroft, T. Schär, I.
21 Nissen, N. Santacroce, E. Burcklen, P. Ferreira, K. P. Jablonski, S. Posada-Céspedes, V. Capece,
22 S. Seidel, N. S. de Souza, J. M. Martinez-Gomez, P. Cheng, P. P. Bosshard, M. P. Levesque, V.
23 Kufner, S. Schmutz, M. Zaheri, M. Huber, A. Trkola, S. Cordey, F. Laubscher, A. R. Gonçalves,
24 S. Aeby, T. Pilonel, D. Jacot, C. Bertelli, G. Greub, K. Leuzinger, M. Stange, A. Mari, T.
25 Roloff, H. Seth-Smith, H. H. Hirsch, A. Egli, M. Redondo, O. Kobel, C. Noppen, L. du Plessis,
26 N. Beerenwinkel, R. A. Neher, C. Beisel, T. Stadler, Swiss public health measures associated
27 with reduced SARS-CoV-2 transmission using genome data. *Sci. Transl. Med.* (2022), doi:
28 10.1101/2021.11.11.21266107.
- 29 9. N. Anderegg, T. Schwab, L. Borcard, C. Mugglin, B. Keune-Dübi, A. Ramette, L. Fenner,
30 Population-based SARS-CoV-2 whole genome sequencing and contact tracing during the
31 COVID-19 pandemic in Switzerland. *J. Infect. Dis.* **27**, jiad074 (2023). doi:
32 10.1093/infdis/jiad074.
- 33 10. J. Douglas, F. K. Mendes, R. Bouckaert, D. Xie, C. L. Jiménez-Silva, C. Swanepoel, J. de
34 Ligt, X. Ren, M. Storey, J. Hadfield, C. R. Simpson, J. L. Geoghegan, A. J. Drummond, D.
35 Welch, Phylodynamics Reveals the Role of Human Travel and Contact Tracing in Controlling
36 the First Wave of COVID-19 in Four Island Nations. *Virus Evol.* **7**, (2021). doi:
37 10.1093/ve/veab052.
- 38 11. N. Banholzer, A. Lison, D. Özcelik, T. Stadler, S. Feuerriegel, W. Vach, The methodologies
39 to assess the effectiveness of non-pharmaceutical interventions during COVID-19: a systematic
40 review. *Eur. J. Epidemiol.* **37**, 1003–1024 (2022). doi: 10.1007/s10654-022-00908-y.

- 1 12. A. Lison, N. Banholzer, M. Sharma, S. Mindermann, H. J. T. Unwin, S. Mishra, T. Stadler,
2 S. Bhatt, N. M. Ferguson, J. Brauner, W. Vach, Effectiveness assessment of non-pharmaceutical
3 interventions: lessons learned from the COVID-19 pandemic. *Lancet Public Heal.* **8**, e311–e317
4 (2023). doi: 10.1016/S2468-2667(23)00046-4.
- 5 13. T. I. Vasylyeva, C. E. Fang, M. Su, J. L. Havens, E. Parker, J. C. Wang, M. Zeller, A.
6 Yakovleva, G. W. Hassler, M. A. Chowdhury, K. G. Andersen, S. Hughes, J. O. Wertheim,
7 Introduction and Establishment of SARS-CoV-2 Gamma Variant in New York City in Early
8 2021. *J. Infect. Dis.* **226**(12), 2142-2149J (2022). doi: 10.1093/infdis/jiac265.
- 9 14. A. Henschel, S. F. Feng, R. A. Hamoudi, G. D. Elbait, E. Damiani, F. Waasia, G. K. Tay, B.
10 H. Mahboub, M. H. Uddin, J. Acuna, E. Alefishat, R. Halwani, H. F. Jelinek, F. Mustafa, N.
11 Alkaabi, H. S. Alsafar, U. C.-19 C. Partnership, Travel ban effects on SARS-CoV-2 transmission
12 lineages in the UAE as inferred by genomic epidemiology. *PLoS One.* **17**, e0264682 (2022). doi:
13 10.1371/journal.pone.0264682.
- 14 15. H. Gu, R. Xie, D. C. Adam, J. L.-H. Tsui, D. K. Chu, L. D. J. Chang, S. S. Y. Cheuk, S.
15 Gurung, P. Krishnan, D. Y. M. Ng, G. Y. Z. Liu, C. K. C. Wan, S. S. M. Cheng, K. M. Edwards,
16 K. S. M. Leung, J. T. Wu, D. N. C. Tsang, G. M. Leung, B. J. Cowling, M. Peiris, T. T. Y. Lam,
17 V. Dhanasekaran, L. L. M. Poon, Genomic epidemiology of SARS-CoV-2 under an elimination
18 strategy in Hong Kong. *Nat Commun.* **13**, 736 (2022). doi: 10.1038/s41467-022-28420-7.
- 19 16. H. Tegally, E. Wilkinson, J. L.-H. Tsui, M. Moir, D. Martin, A. F. Brito, M. Giovanetti, K.
20 Khan, C. Huber, I. I. Bogoch, J. E. San, J. Poongavanan, J. S. Xavier, D. da S. Candido, F.
21 Romero, C. Baxter, O. G. Pybus, R. Lessells, N. R. Faria, M. U. G. Kraemer, T. de Oliveira,
22 Dispersal Patterns and Influence of Air Travel During the Global Expansion of SARS-CoV-2
23 Variants of Concern. *Cell.* **186**(15), 3277-3290.e16. (2023). doi: 10.1016/j.cell.2023.06.001.
- 24 17. A. Couture, A. D. Iuliano, H. H. Chang, N. N. Patel, M. Gilmer, M. Steele, F. P. Havers, M.
25 Whitaker, C. Reed, Estimating COVID-19 Hospitalizations in the United States With
26 Surveillance Data Using a Bayesian Hierarchical Model: Modeling Study. *JMIR Public Heal.*
27 *Surveill.* **8**, e34296 (2022). doi: 10.2196/34296.
- 28 18. Canadian Institute for Health Information, COVID-19 hospitalization and emergency
29 department statistics (2023) [https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-](https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-department-statistics)
30 [department-statistics](https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-department-statistics).
- 31 19. C. L. Murall, R. Poujol, S. A. Kraemer, A. Zetner, A. Pekau, B. Sobkowiak, E. Gill, A.
32 N'Guessan, S. Naderia, J. Fritz, F. Brinkman, J. Hussin, C. Colijn, G. V. Domselaar, S. P. Otto,
33 B. J. Shapiro, T. C. C.-19 G. N. (CanCOGeN), Monitoring the growth and evolution of Delta
34 sublineages AY.25 and AY.27 in Canada. *Virological.org* [Preprint] (2021)
35 [https://virological.org/t/monitoring-the-evolution-and-spread-of-delta-sublineages-ay-25-and-ay-](https://virological.org/t/monitoring-the-evolution-and-spread-of-delta-sublineages-ay-25-and-ay-27-in-canada/767)
36 [27-in-canada/767](https://virological.org/t/monitoring-the-evolution-and-spread-of-delta-sublineages-ay-25-and-ay-27-in-canada/767).

- 1 20. W. S. Hart, E. Miller, N. J. Andrews, P. Waight, P. K. Maini, S. Funk, R. N. Thompson,
2 Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis.
3 *Lancet Infect. Dis.* **22**(5), 603-610, (2022). doi: 10.1016/s1473-3099(22)00001-9.
- 4 21. L. Jelley, J. Douglas, X. Ren, D. Winter, A. McNeill, S. Huang, N. French, D. Welch, J.
5 Hadfield, J. de Ligt, J. L. Geoghegan, Genomic epidemiology of Delta SARS-CoV-2 during
6 transition from elimination to suppression in Aotearoa New Zealand. *Nat. Commun.* **13**, 4035
7 (2022). doi: 10.1038/s41467-022-31784-5.
- 8 22. D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. M. Rajah, C.
9 Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. L. Guen,
10 N. Kassis-Chikhani, D. Edriss, L. Belec, A. Seve, L. Courtellemont, H. Péré, L. Hocqueloux, S.
11 Fafi-Kremer, T. Prazuck, H. Mouquet, T. Bruel, E. Simon-Lorière, F. A. Rey, O. Schwartz,
12 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature.* **596**, 276–
13 280 (2021). doi: 10.1038/s41586-021-03777-9.
- 14 23. S. Talic, S. Shah, H. Wild, D. Gasevic, A. Maharaj, Z. Ademi, X. Li, W. Xu, I. Mesa-
15 Eguiagaray, J. Rostron, E. Theodoratou, X. Zhang, A. Motee, D. Liew, D. Ilic, Effectiveness of
16 public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and
17 covid-19 mortality: systematic review and meta-analysis. *BMJ.* **375**, e068302 (2021). doi:
18 10.1136/bmj-2021-068302.
- 19 24. T. Mashe, F. T. Takawira, L. de O. Martins, M. Gudza-Mugabe, J. Chirenda, M. Munyanyi,
20 B. V. Chaibva, A. Tarupiwa, H. Gumbo, A. Juru, C. Nyagupe, V. Ruhanya, I. Phiri, P.
21 Manangazira, A. Goredema, S. Danda, I. Chabata, J. Jonga, R. Munharira, K. Masunda, I.
22 Mukeredzi, D. Mangwanya, A. Trotter, T. L. Viet, S. Rudder, G. Kay, D. Baker, G. Thilliez, A.
23 V. Gutierrez, J. O’Grady, M. Hove, S. Mutapuri-Zinyowera, A. J. Page, R. A. Kingsley, G.
24 Mhlanga, COVID-19 Genomics UK Consortium, SARS-CoV-2 Research Group, Genomic
25 epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in
26 Zimbabwe: a retrospective study of routinely collected surveillance data. *Lancet Global Heal.* **9**,
27 e1658–e1666 (2021). doi: 10.1016/S2214-109X(21)00434-4.
- 28 25. J.-H. Kwon, J.-M. Kim, D. Lee, A. K. Park, I.-H. Kim, D.-W. Kim, J.-Y. Kim, N. Lim, K.-Y.
29 Cho, H. M. Kim, N.-J. Lee, S. Woo, C. Y. Lee, J. S. No, J. Kim, J. Rhee, M.-G. Han, G.-E. Rhie,
30 C. K. Yoo, E.-J. Kim, Genomic epidemiology reveals the reduction of the introduction and
31 spread of SARS-CoV-2 after implementing control strategies in Republic of Korea, 2020. *Virus*
32 *Evol.* **7**, veab077 (2021). doi: 10.1093/ve/veab077.
- 33 26. J. T. McCrone, V. Hill, S. Bajaj, R. E. Pena, B. C. Lambert, R. Inward, S. Bhatt, E. Volz, C.
34 Ruis, S. Dellicour, G. Baele, A. E. Zarebski, A. Sadilek, N. Wu, A. Schneider, X. Ji, J.
35 Raghwani, B. Jackson, R. Colquhoun, Á. O’Toole, T. P. Peacock, K. Twohig, S. Thelwall, G.
36 Dabrera, R. Myers, T. COVID-19 Genomics UK (COG-UK) Consortium, N. R. Faria, C. Huber,
37 I. I. Bogoch, K. Khan, L. du Plessis, J. C. Barrett, D. M. Aanensen, W. S. Barclay, M. Chand, T.
38 Connor, N. J. Loman, M. A. Suchard, O. G. Pybus, A. Rambaut, M. U. G. Kraemer, Context-
39 specific emergence and growth of the SARS-CoV-2 Delta variant. *Nature.* **610**, 154–160 (2022).
40 doi: 10.1038/s41586-022-05200-3.

- 1 27. R. Viana, S. Moyo, D. G. Amoako, H. Tegally, C. Scheepers, C. L. Althaus, U. J. Anyaneji,
2 P. A. Bester, M. F. Boni, M. Chand, W. T. Choga, R. Colquhoun, M. Davids, K. Deforche, D.
3 Doolabh, L. du Plessis, S. Engelbrecht, J. Everatt, J. Giandhari, M. Giovanetti, D. Hardie, V.
4 Hill, N.-Y. Hsiao, A. Iranzadeh, A. Ismail, C. Joseph, R. Joseph, L. Koopile, S. L. K. Pond, M.
5 U. G. Kraemer, L. Kuate-Lere, O. Laguda-Akingba, O. Lesetedi-Mafoko, R. J. Lessells, S.
6 Lockman, A. G. Lucaci, A. Maharaj, B. Mahlangu, T. Maponga, K. Mahlakwane, Z. Makatini,
7 G. Marais, D. Maruapula, K. Masupu, M. Matshaba, S. Mayaphi, N. Mbhele, M. B. Mbulawa, A.
8 Mendes, K. Mlisana, A. Mnguni, T. Mohale, M. Moir, K. Moruisi, M. Mosepele, G. Motsatsi,
9 M. S. Motswaledi, T. Mphoyakgosi, N. Msomi, P. N. Mwangi, Y. Naidoo, N. Ntuli, M. Nyaga,
10 L. Olubayo, S. Pillay, B. Radibe, Y. Ramphal, U. Ramphal, J. E. San, L. Scott, R. Shapiro, L.
11 Singh, P. Smith-Lawrence, W. Stevens, A. Strydom, K. Subramoney, N. Tebeila, D. Tshiabuila,
12 J. Tsui, S. van Wyk, S. Weaver, C. K. Wibmer, E. Wilkinson, N. Wolter, A. E. Zarebski, B.
13 Zuze, D. Goedhals, W. Preiser, F. Treurnicht, M. Venter, C. Williamson, O. G. Pybus, J.
14 Bhiman, A. Glass, D. P. Martin, A. Rambaut, S. Gaseitsiwe, A. von Gottberg, T. de Oliveira,
15 Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature*. **603**,
16 679–686 (2022). doi: 10.1038/s41586-022-04411-y.
- 17 28. Government of Canada, Current travel restrictions—Standing Committee on Health:
18 Emergency Situation Facing Canadians in Light of the COVID-19 Pandemic (2021),
19 [https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-](https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-21/travrestrict-restrictvoya-eng.html)
20 [21/travrestrict-restrictvoya-eng.html](https://www.cbsa-asfc.gc.ca/transparency-transparence/pd-dp/bbp-rpp/hesa/2021-05-21/travrestrict-restrictvoya-eng.html).
- 21 29. British Columbia COVID-19 Modelling Group, COVID Model Projections February 4, 2022
22 (2022). <https://bccovid-19group.ca/>
- 23 30. P. Liu, Y. Song, C. Colijn, A. MacPherson, The impact of sampling bias on viral
24 phylogeographic reconstruction. *PLOS Global Public Heal.* **2**, e0000577 (2022). doi:
25 10.1371/journal.pgph.0000577.
- 26 31. P. Lemey, S. L. Hong, V. Hill, G. Baele, C. Poletto, V. Colizza, Á. O’Toole, J. T. McCrone,
27 K. G. Andersen, M. Worobey, M. I. Nelson, A. Rambaut, M. A. Suchard, Accommodating
28 individual travel history and unsampled diversity in Bayesian phylogeographic inference of
29 SARS-CoV-2. *Nature Communications*. **11**, 1–14 (2020). doi: 10.1038/s41467-020-18877-9.
- 30 32. C. Colijn, D. J. Earn, J. Dushoff, N. H. Ogden, M. Li, N. Knox, G. V. Domselaar, K.
31 Franklin, G. Jolly, S. P. Otto, The need for linked genomic surveillance of SARS-CoV-2. *Can.*
32 *Commun. Dis. Rep.* **48**, 131–139 (2022). doi: 10.14745/ccdr.v48i04a03.
- 33 33. S. Mishra, J. D. Walker, L. Wilhelm, V. Larivière, T. Bubela, S. E. Straus, Use and misuse of
34 research: Canada’s response to COVID-19 and its health inequalities. *BMJ*. **382**, e075666
35 (2023). doi: 10.1136/bmj-2023-075666.
- 36 34. T. Bubela, C. M. Flood, K. McGrail, S. E. Straus, S. Mishra, How Canada’s decentralised
37 covid-19 response affected public health data and decision making. *BMJ*. **382**, e075665 (2023).
38 doi: 10.1136/bmj-2023-075665.

- 1 35. T. H. To, M. Jung, S. Lycett, O. Gascuel, Fast dating using least-squares criteria and
2 algorithms. *Systematic Biology*. **65**, 82–97 (2016). doi: 10.1093/sysbio/syv068.
- 3 36. S. P. Otto, T. Day, J. Arino, C. Colijn, J. Dushoff, M. Li, S. Mechai, G. V. Domselaar, J. Wu,
4 D. J. D. Earn, N. H. Ogden, The origins and potential future of SARS-CoV-2 variants of concern
5 in the evolving COVID-19 pandemic. *Curr Biol*. **31**, R918–R929 (2021). doi:
6 10.1016/j.cub.2021.06.049.
- 7 37. M. D. Figgins, T. Bedford, SARS-CoV-2 variant dynamics across US states show consistent
8 differences in effective reproduction numbers, *Medrxiv* [Preprint] (2022) doi:
9 10.1101/2021.12.09.21267544.
- 10 38. J. E. Stockdale, P. Liu, C. Colijn, The potential of genomics for infectious disease
11 forecasting. *Nat. Microbiol*. **7**, 1736–1743 (2022). doi: 10.1038/s41564-022-01233-6.
- 12 39. K. Koelle, M. A. Martin, R. Antia, B. Lopman, N. E. Dean, The changing epidemiology of
13 SARS-CoV-2. *Science*. **375**, 1116–1121 (2022). doi: 10.1126/science.abm4915.
- 14 40. Y. Shu, J. McCauley, GISAID: Global initiative on sharing all influenza data – from vision
15 to reality. *Eurosurveillance*. **22**, 30494 (2017). doi: 10.2807/1560-7917.ES.2017.22.13.30494.
- 16 41. S. Khare, C. Gurry, L. Freitas, M. B. Schultz, G. Bach, A. Diallo, N. Akite, J. Ho, R. T. Lee,
17 W. Yeo, GISAID Core Curation Team, S. Maurer-Stroh, GISAID’s Role in Pandemic Response.
18 *China CDC Wkly*. **3**, 1049–1051 (2021). doi: 10.46234/ccdcw2021.255.
- 19 42. T. Bedford, nextstrain/ncov (2021), <https://github.com/nextstrain/ncov>.
- 20 43. N. Moshiri, ViralMSA: Massively scalable reference-guided multiple sequence alignment of
21 viral genomes. *Bioinformatics*. **37**, 714–716 (2020). doi: 10.1093/bioinformatics/btaa743.
- 22 44. H. Li, Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*. **34**, 3094–
23 3100 (2018). doi: 10.1093/bioinformatics/bty191.
- 24 45. Á. O’Toole, E. Scher, A. Underwood, B. Jackson, V. Hill, J. T. McCrone, R. Colquhoun, C.
25 Ruis, K. Abu-Dahab, B. Taylor, C. Yeats, L. D. Plessis, D. Maloney, N. Medd, S. W. Attwood,
26 D. M. Aanensen, E. C. Holmes, O. G. Pybus, A. Rambaut, Assignment of Epidemiological
27 Lineages in an Emerging Pandemic Using the Pangolin Tool. *Virus Evol*. **7**(2), veab064- (2021).
28 doi: 10.1093/ve/veab064.
- 29 46. K. Gangavarapu, A. A. Latif, J. L. Mullen, M. Alkuzweny, E. Hufbauer, G. Tsueng, E. Haag,
30 M. Zeller, C. M. Aceves, K. Zaiets, M. Cano, X. Zhou, Z. Qian, R. Sattler, N. L. Matteson, J. I.
31 Levy, R. T. C. Lee, L. Freitas, S. Maurer-Stroh, GISAID Core and Curation Team, M. A.
32 Suchard, C. Wu, A. I. Su, K. G. Andersen, L. D. Hughes, Outbreak.info genomic reports:
33 scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. *Nat. Methods*. **20**,
34 512–522 (2023). doi: 10.1038/s41592-023-01769-3.

- 1 47. Public Health Agency of Canada, “Coronavirus disease 2019 (COVID-19): Epidemiology
2 update” (Government of Canada, Ottawa, ON, 2021), [https://health-infobase.canada.ca/covid-
3 19/epidemiological-summary-covid-19-cases.html?stat=num&;measure=active#a2](https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html?stat=num&;measure=active#a2).
- 4 48. R. Krispin, J. Byrnes, coronavirus: The 2019 Novel Coronavirus COVID-19 (2019-nCoV)
5 Dataset. R package version 0.3.0. <https://github.com/RamiKrispin/coronavirus> (2020);
6 <https://cran.r-project.org/web/packages/coronavirus/coronavirus.pdf>.
- 7 49. S. A. Nadeau, T. G. Vaughan, J. Scire, J. S. Huisman, T. Stadler, The origin and early spread
8 of SARS-CoV-2 in Europe. *Proc. National Acad. Sci.* **118**, e2012008118 (2021). doi:
9 10.1073/pnas.2012008118.
- 10 50. N. de Maio, C. Walker, R. Borges, L. Weilguny, G. Slodkowitz, N. Goldman, Masking
11 strategies for SARS-CoV-2 alignments. *virological.org [Preprint]*. (2020).
12 virological.org/t/masking-strategies-for-sars-cov-2-alignments/480.
- 13 51. M. N. Price, P. S. Dehal, A. P. Arkin, FastTree 2--approximately maximum-likelihood trees
14 for large alignments. *PLoS ONE*. **5**, e9490 (2010). doi: 10.1371/journal.pone.0009490.
- 15 52. E. Paradis, K. Schliep, ape 5.0: an environment for modern phylogenetics and evolutionary
16 analyses in R. *Bioinformatics*. **35**, 526–528 (2018). doi: 10.1093/bioinformatics/bty633.
- 17 53. B. Q. Minh, H. A. Schmidt, O. Chernomor, D. Schrempf, M. D. Woodhams, A. von
18 Haeseler, R. Lanfear, IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
19 Inference in the Genomic Era. *Molec. Biol. and Evol.* **37**, 1530–1534 (2020). doi:
20 10.1093/molbev/msaa015.
- 21 54. Statistics Canada, Table 24-10-0056-01 Leading indicator, International visitors entering or
22 returning to Canada by air, by country of residence and traveller type (2023),
23 <https://doi.org/10.25318/2410005601-eng>.

24

25 **Acknowledgments:**

26 We gratefully acknowledge all originating and submitting laboratories of SARS-CoV-2 genome
27 sequences and metadata on GISAID. We also thank members of the Canadian COVID-19
28 Genomics Network (CanCOGeN) Consortium (**Supplementary file of contributions**) and the
29 Canadian Public Health Laboratory Network (CPHLN) for their contributions towards publicly
30 available data.

31

32 **Funding:**

33 AM was supported by a Canada Graduate Scholarship Doctoral Award from the Canadian
34 Institutes for Health Research.

35 AM, VM, RLM, and JBJ received funding from the British Columbia Centre for Excellence in
36 HIV/AIDS and Providence Healthcare.

1 MW was supported by funding from the Centers of Excellence for Influenza Research and
2 Response (CEIRR).

3 JBJ was supported by an operating grant from the Canadian Institutes of Health Research
4 Coronavirus Rapid Response Programme grant number 440371 and a Canadian Institutes for
5 Health Research Variant of Concern Grant.

6

7 **Author contributions:**

8 Conceptualization: AM, JBJ.

9 Methodology: AM, VM, JBJ

10 Investigation: AM

11 Visualization: AM

12 Funding acquisition: AM, JBJ

13 Project administration: JBJ

14 Supervision: JBJ

15 Writing – original draft: AM, JBJ

16 Writing – review & editing: AM, VM, RLM, MW, JBJ

17

18 **Competing interests:** The authors declare no competing interests.

19

20 **Data and materials availability:**

21 Viral genome sequences analyzed in this study were sourced from the Global initiative on
22 sharing all influenza data (GISAID) coronavirus (CoV) database and are subject to the GISAID
23 EpiFlu Database Access Agreement. Within this agreement, we cannot distribute data to any
24 third part other than Authorized Users. A full set of all subsampled genome sequence accession
25 IDs is available at GISAID EPI_SET_230510yr (doi:10.55876/gis8.230510yr), which serves as
26 the data acknowledgement for all originating and submitting laboratories. Those without
27 GISAID access credentials may retrieve information about all data contributors by either clicking
28 on the DOI or pasting the EPI_SET ID in the "Data Acknowledgement Locator" on the GISAID
29 homepage. Full and subsampled alignments can be shared to Authorized Users upon request.
30 Scripts used for data curation, inferences, analyses, and visualization are available at
31 github.com/AngMcL/sc2_canada_variants.

32

33 **Supplementary materials**

34 Materials and Methods

35 Supplementary Text

36 Figs. S1 to S53

37 Tables S1 to S3

38 References (1-13)